Platinum–Acridine Agents with High Activity in Cancers Expressing the Solute Carrier MATE1 (SLC47A1)

13 June 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Platinum–acridine anticancer agents (PAs) containing acyclic (1 and 3) and heterocyclic (R)-3-aminopiperidine (2) and 2-iminopyrrolidine (4) based linker moieties were studied. Similar to 1, rigidified 2 shows a strong positive correlation between potency and SLC47A1 (multi-drug and toxin extrusion protein 1, MATE1) gene expression levels across the NCI-60 panel of cancer cell lines. All derivatives show nanomolar activity in HepG2 (liver), NCI-H460 (lung), and MDA-MB-436 (breast), which express high levels of SLC47A1 (Cancer Cell Line Encyclopedia, CCLE). The PAs are up to 350-fold more potent than cisplatin. In a MATE1 inhibition assay, a significant reduction in activity is observed in the three cancer cell lines (4000-fold lower for HepG2). Molecular docking experiments provide insight into the compatibility of a structurally diverse set of PAs with MATE1-mediated transport. MATE1 is a predictive marker and actionable target that sensitizes cancer cells regardless of tissue of origin to PAs.

Keywords

membrane transporter
chemosensitivity
heterocyclic amidines
gene expression
DNA-targeted anticancer agents

Supplementary materials

Title
Description
Actions
Title
Supporting Info
Description
Experimental details, synthetic procedures and details of compound characterization and purity (1H NMR and 13C NMR spectra, MS data, and HPLC traces), 2-D NMR solution and X-ray crystallographic characterization of compound 4, additional molecular docking results, and figures/tables summarizing cytotoxicity and SLC47A1 expression data.
Actions
Title
CIF file
Description
CIF file for crystal structure of compound 4
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.